Cantor Fitzgerald Predicts PVLA FY2025 Earnings

Palvella Therapeutics (NASDAQ:PVLA - Free Report) - Cantor Fitzgerald issued their FY2025 earnings per share estimates for Palvella Therapeutics in a research report issued on Monday, May 19th. Cantor Fitzgerald analyst J. Schimmer expects that the company will post earnings per share of ($2.60) for the year. The consensus estimate for Palvella Therapeutics' current full-year earnings is ($3.69) per share.

Several other research firms have also recently commented on PVLA. HC Wainwright restated a "buy" rating and issued a $38.00 target price on shares of Palvella Therapeutics in a research report on Wednesday, April 30th. TD Cowen initiated coverage on shares of Palvella Therapeutics in a research note on Wednesday, February 5th. They set a "buy" rating and a $44.00 price objective on the stock. Jones Trading started coverage on shares of Palvella Therapeutics in a report on Tuesday, March 25th. They issued a "buy" rating and a $45.00 price objective for the company. Chardan Capital initiated coverage on shares of Palvella Therapeutics in a research note on Wednesday, April 9th. They set a "buy" rating and a $50.00 target price on the stock. Finally, Stifel Nicolaus assumed coverage on shares of Palvella Therapeutics in a research report on Wednesday, March 26th. They set a "buy" rating and a $45.00 price target on the stock. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $46.29.

Palvella Therapeutics Stock Performance

PVLA opened at $23.23 on Wednesday. The company's 50 day simple moving average is $24.40. The company has a market capitalization of $256.53 million, a PE ratio of -1.92 and a beta of 0.10. Palvella Therapeutics has a twelve month low of $6.20 and a twelve month high of $29.27.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.74) earnings per share for the quarter, beating the consensus estimate of ($3.40) by $2.66.

Insider Buying and Selling at Palvella Therapeutics

In other Palvella Therapeutics news, Director George M. Jenkins bought 2,500 shares of the company's stock in a transaction that occurred on Wednesday, April 9th. The shares were acquired at an average cost of $20.13 per share, for a total transaction of $50,325.00. Following the acquisition, the director now directly owns 183,171 shares of the company's stock, valued at $3,687,232.23. This trade represents a 1.38% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. 20.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Spire Wealth Management acquired a new stake in shares of Palvella Therapeutics during the 1st quarter valued at $70,000. Citadel Advisors LLC purchased a new stake in shares of Palvella Therapeutics during the fourth quarter valued at $125,000. Toronto Dominion Bank acquired a new position in shares of Palvella Therapeutics in the 4th quarter valued at $159,000. Geode Capital Management LLC acquired a new position in shares of Palvella Therapeutics in the 4th quarter valued at $171,000. Finally, Goldman Sachs Group Inc. acquired a new position in shares of Palvella Therapeutics in the 1st quarter valued at $533,000. Institutional investors and hedge funds own 40.11% of the company's stock.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.